T2 Biosystems, Inc.

Equities

TTOO

US89853L3024

Advanced Medical Equipment & Technology

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-13 pm EDT			5-day change	1st Jan Change
4.39 ^USD	+18.81%		+20.94%	-30.04%

May. 07	T2 Biosystems Announces Letter of Intent to Enter Strategic Partnership for Lyme Disease	CI
May. 07	North American Morning Briefing : Stock Futures Muted After Rally Fueled by Rate-Cut Hopes	DJ

T2 Biosystems, Inc. Provides Revenue Guidance for the Year 2023

July 12, 2023 at 08:30 am EDT

T2 Biosystems, Inc. provided revenue guidance for the year 2023. For the year, Company now expects total sepsis and related product revenue ofÂ $9.5 millionÂ toÂ $10.5 million, representing growth of 13% to 25%, compared toÂ $8.4 millionÂ in 2022.

Latest news about T2 Biosystems, Inc.

T2 Biosystems Announces Letter of Intent to Enter Strategic Partnership for Lyme Disease	May. 07	CI
North American Morning Briefing : Stock Futures Muted After Rally Fueled by Rate-Cut Hopes	May. 07	DJ
T2 Biosystems, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 06	CI
Earnings Flash (TTOO) T2 BIOSYSTEMS Posts Q1 Revenue $2.1M	May. 06	MT
T2 Biosystems, Inc. Reiterates Revenue Guidance for the Full Year 2024	May. 06	CI
T2 Biosystems, Inc. Announces Commercial Expansion Through Middle East Distributor	May. 06	CI
Transcript : T2 Biosystems, Inc., Q1 2024 Earnings Call, May 06, 2024	May. 06
Canaccord Genuity Adjusts Price Target on T2 Biosystems to $3 From $12, Maintains Hold Rating	Apr. 29	MT
Top Premarket Decliners	Apr. 23	MT
T2 Biosystems, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 01	CI
T2 Biosystems Announces Extension of Multi-Year Capital Equipment Supplier Agreement with Vizient, Inc	Mar. 28	CI
T2 Biosystems, Inc. Reiterates Revenue Guidance for the Year 2024	Mar. 20	CI
Transcript : T2 Biosystems, Inc. - Special Call	Mar. 20
T2 Biosystems Unveils T2Lyme Launch Plans and Provides Additional Business Updates	Mar. 20	CI
T2 Biosystems, Inc. Announces Publication of New Study Highlighting Clinical Benefits and Performance of Real-World Use of T2Resistance Panel in Journal of Clinical Microbiology	Mar. 18	CI
Transcript : T2 Biosystems, Inc., Q4 2023 Earnings Call, Feb 15, 2024	Feb. 15
T2 Biosystems, Inc. Announces Commercial Expansion Through Distributors in Europe and Asia	Feb. 15	CI
Sector Update: Health Care Stocks Mixed Late Afternoon	Feb. 12	MT
Sector Update: Health Care Stocks Steady in Afternoon Trading	Feb. 12	MT
T2 Biosystems Gets FDA Clearance for Expanded T2Bacteria Panel; Shares Rise	Feb. 12	MT
T2 Biosystems Gets 510(k) Clearance For Expanded T2Bacteria Panel	Feb. 12	DJ
T2 Biosystems Receives FDA 510(k) Clearance for the Expanded T2Bacteria Panel	Feb. 12	CI
T2 Biosystems Announces Participation in NIH-Funded Antibacterial Resistance Leadership Group Pilot Study for Pneumonia Patients	Jan. 18	CI
T2 Biosystems, Inc. Announces the Resignation of Thierry Bernard as Class II Director and All Committees of the Board of Directors	Jan. 05	CI
T2 Biosystems, Inc. Announces FDA 510(K) Submission to Expand Use of the FDA-Cleared T2candida Panel to Include Pediatric Testing	Jan. 03	CI

Chart T2 Biosystems, Inc.

Duration

Period

More charts

Company Profile

T2 Biosystems, Inc. is an in vitro diagnostics company focused on the detection of sepsis-causing pathogens and antibiotic resistance genes. Its technology enables detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as low as one colony forming unit per milliliter (CFU/mL). Its focus includes three areas: sepsis, bioterrorism, and Lyme disease. The Company's products include the T2Dx Instrument, the T2Bacteria Panel, the T2Candida Panel, the T2Resistance Panel, and the T2Biothreat Panel, and are powered by the T2 Magnetic Resonance (T2MR) technology. It also has an active pipeline of products, including the United States T2Resistance Panel, the Candida auris test, and the T2Lyme Panel. T2Dx Instrument is a fully automated instrument that is capable of running a range of diagnostic tests from patient samples.

Sector

Advanced Medical Equipment & Technology

Calendar

2024-07-30 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

4.39 USD

Average target price

3 USD

Spread / Average Target

-31.66%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
T2 BIOSYSTEMS, INC.	-30.04%	59.45M
THERMO FISHER SCIENTIFIC	+11.29%	225B
DANAHER CORPORATION	+8.76%	186B
INTUITIVE SURGICAL, INC.	+12.90%	135B
BOSTON SCIENTIFIC CORPORATION	+25.95%	107B
SIEMENS HEALTHINEERS AG	+0.15%	63.56B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	+5.62%	51.32B
EDWARDS LIFESCIENCES CORPORATION	+11.08%	51.04B
AGILENT TECHNOLOGIES, INC.	+6.28%	43.3B
GE HEALTHCARE TECHNOLOGIES INC.	+4.80%	36.99B

Other Advanced Medical Equipment & Technology